Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Rituximab 25Lenalidomide 21Cyclophosphamide 20Prednisone 14obinutuzumab 12Vincristine 12Doxorubicin 11Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 9Specimen Handling 8ibrutinib 7Biopsy 7fludarabine 6pembrolizumab 5fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Prednisolone 3Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × belinostat × 90 days × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡